Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. For 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines as well as supportive technologies and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion leads with the knowledge that patients and caregivers are people first, and by seeking to understand their experiences, Alexion is better able to serve their unique needs.
Alexion’s pioneering legacy in rare diseases is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion continues to push the boundaries of science to accelerate the discovery and development of new life-changing medicines for even more people affected by rare diseases. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and continues to expand its reach to benefit the lives of more rare disease patients around the world.
For more information, please visit www.alexion.com.
Alexion/MCPHS Fellowship Program
Alexion, in collaboration with MCPHS, is pleased to offer four unique postdoctoral fellowship programs to expose qualified Doctor of Pharmacy graduates to the biopharmaceutical industry, and to enhance the role of pharmacists within this field. Each fellowship is two years in duration and will be based out of Alexion's headquarters in Boston, Massachusetts:
The fellowship programs are:
- Global Patient Safety: 1 Position
- Global Medical Communications/Global Medical Affairs: 3 Positions
- Global Regulatory Affairs: 1 position
- Global Value, Access, and Pricing: 1 position
- US Medical Affairs: 1 position
Please see our brochure for additional details.
If you have any questions, please contact us at PharmD.Fellowships@alexion.com.